Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report

Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report

Abstract Background Anthracyclines are highly effective anticancer medication prescribed for the treatment of breast cancer. Nevertheless, the use of anthracyclines as chemotherapeutic agents involves a risk for development of cardiac toxicity which may cause restrictive and dilated cardiomyopathy....

Full description

Bibliographic Details
Main Authors: Jock Chichaco Kuruc, Armando A. Durant-Archibold, Jorge Motta, K. S. Rao, Barry Trachtenberg, Carlos Ramos, Hongyu Wang, David Gorenstein, Fredrik Vannberg, King Jordan
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Cardiovascular Disorders
Subjects:
Cardiotoxicity
Dilated cardiomyopathy
Antrhacyclines
LMNA gene
Breast cancer
Online Access:http://link.springer.com/article/10.1186/s12872-019-1155-7

Internet

http://link.springer.com/article/10.1186/s12872-019-1155-7

Similar Items